Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has been effective faithfully but unsuccessfully to produce a single therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be used is actually an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as a combination therapy in the therapy of multi-drug-resistant HIV have been closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of my past several shares. My first CytoDyn article, “CytoDyn: What to be able to Do When It is Too Good to be able to Be True?”, set out what follows prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan offered such an extremely promotional image in the Uptick Newswire interview which I came away with a poor opinion of the business.

Irony of irony, my bad opinion of the business has grown steadily, yet the disappointment hasn’t been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger at the moment still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much-storied treatment (which I shall refer to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the treatment and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s payment of $3.5 huge number of transfers ownership of the technology as well as linked intellectual property coming from Progenics to CytoDyn, as well as approximately 25 million mg of majority drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 zillion) plus the first new drug application approval ($5 million), as well as royalty payments of five percent of net sales after commercialization.

Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to acquire a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous therapies and numerous indications, it has this single therapies in addition to a “broad pipeline of indications” since it places it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially advantageous therapy in dozens of indications.

The opening banner of its on its site (below) shows an active company with diverse interests albeit centered on leronlimab, several disease sorts, multiple delivering presentations in addition to multiple publications.

Can all this be smoke and mirrors? That is a question I’ve been asking myself from the very beginning of my interest in this organization. Judging by the multiples of thousands of diverse remarks on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this question.

CytoDyn is a traditional battleground, or maybe some could say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *